- Home
- RARE vs DAVE Comparison
RARE vs DAVE Comparison
Compare RARE & DAVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | DAVE |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | DAVE |
|---|---|---|
| Price | $23.18 | $194.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 6 |
| Target Price | $66.32 | ★ $282.17 |
| AVG Volume (30 Days) | ★ 2.1M | 453.2K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $17.23 | $59.30 |
| Revenue Next Year | $36.13 | $17.98 |
| P/E Ratio | ★ N/A | $17.85 |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.41 | $65.46 |
| 52 Week High | $43.22 | $286.45 |
Technical Indicators
Market Signals| Indicator | RARE | DAVE |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 56.62 |
| Support Level | $22.00 | $182.68 |
| Resistance Level | $25.46 | $194.00 |
| Average True Range (ATR) | 1.29 | 11.47 |
| MACD | 0.25 | 3.04 |
| Stochastic Oscillator | 72.03 | 93.62 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.